Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders (2009 - 2026)
Dr Reddys Laboratories' Net Income towards Common Stockholders came in at $132.69 million for fiscal Q2 2027 (quarter ended Sep 30, 2026), down 33.9% from $200.78 million a year earlier but up 183.3% from the prior quarter.
Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, Dr Reddys Laboratories reported Net Income towards Common Stockholders of $363.5 million, down 54.1% year-over-year; for FY2026 (ended Mar 31, 2026), it was $485.48 million, down 26.8% from FY2025.
- Net Income towards Common Stockholders carries a five-year compound annual growth rate of 8.2% (FY2021 to FY2026).
- Going back by fiscal year, Net Income towards Common Stockholders was $663 million in FY2025 (-1.4%), $672.67 million in FY2024 (+19.7%), $561.73 million in FY2023 (+41.9%) and $395.73 million in FY2022 (+21.1%).
- The five-year range for quarterly Net Income towards Common Stockholders is $20.2 million (fiscal Q4 2022) to $221.71 million (fiscal Q3 2025).
- Year-over-year, Net Income towards Common Stockholders has declined for six consecutive quarters, with an average decline of 25.8% over the last eight quarters.
- The fastest year-over-year change in Net Income towards Common Stockholders over five years came in fiscal Q4 2023 (growth of 645.5%), and the weakest in fiscal Q4 2026 (a decline of 88.2%).
- Business Quant data shows RDY's Net Income towards Common Stockholders at $46.85 million (Q1 2027), $24.08 million (Q4 2026) and $159.89 million (Q3 2026) in the three fiscal quarters before Q2 2027.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,251.13 Bn | 1,224.74 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 677.29 Bn | 597.15 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 518.44 Bn | 486.45 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 364.56 Bn | 327.50 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 316.19 Bn | 289.43 Bn | - | - |
| 6 | Astrazeneca | 293.21 Bn | 267.11 Bn | 13.26 Bn | 3.12 Bn |
| 7 | Amgen | 250.58 Bn | 202.23 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 210.08 Bn | 185.19 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.84 Bn | 115.19 Bn | 12.56 Bn | 3.24 Bn |
| 10 | Dr Reddys Laboratories | 12.50 Bn | 11.84 Bn | 472.93 Mn | 132.69 Mn |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 132.69 Mn |
| Jun 30, 2026 | 46.85 Mn |
| Mar 31, 2026 | 24.08 Mn |
| Dec 31, 2025 | 159.89 Mn |
| Sep 30, 2025 | 200.78 Mn |
| Jun 30, 2025 | 165.67 Mn |
| Mar 31, 2025 | 203.79 Mn |
| Dec 31, 2024 | 221.71 Mn |
| Sep 30, 2024 | 209.55 Mn |
| Jun 30, 2024 | 166.87 Mn |
| Mar 31, 2024 | 180.13 Mn |
| Dec 31, 2023 | 207.37 Mn |
| Sep 30, 2023 | 179.04 Mn |
| Jun 30, 2023 | 214.66 Mn |
| Mar 31, 2023 | 785.08 Mn |
| Dec 31, 2022 | 200.06 Mn |
| Sep 30, 2022 | 202.28 Mn |
| Jun 30, 2022 | 158.37 Mn |
| Mar 31, 2022 | 20.20 Mn |
| Dec 31, 2021 | 123.26 Mn |
Dr Reddys Laboratories Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=RDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "RDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=RDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();